Our business model is designed for maximum flexibility, which allows us to pursue a broad range of products and product candidates with high clinical and commercial potential. This broad and deep diversification lowers the overall risk profile of the company. Our unique model enables us to act quickly to seize time-sensitive opportunities whenever necessary and provides us with a wider range of options from which to select the most ideal corporate or financial structure for each drug candidate. We also seek monetization opportunities for each product candidate at the appropriate stage in development.

« Back to Q&A